Eton's ET-700 Pilot: Better Tolerability, Weaker Copper Blocking Than GALZIN
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton reported preliminary ET-700 pilot results: far fewer treatment-related side effects than GALZIN, but weaker inhibition of copper absorption, with faster-release reformulations now slated for 2027 study arms.
Key Events · Product Development and Regulatory · ETON
-
ET-700 Pilot Results Announced
Randomized, double-blind, placebo-controlled study in 36 healthy participants; 29 met per-protocol criteria for the primary copper-uptake analysis.
-
Tolerability Clearly Better Than GALZIN
Treatment-related adverse events occurred in 1 of 12 ET-700 participants versus 8 of 12 on GALZIN (17 total events) and 3 of 12 on placebo; no serious adverse events in any arm.
-
Copper Blocking Weaker Than GALZIN
Hepatic copper uptake fell 12% with ET-700 versus 46% with GALZIN and an 11% increase with placebo; the intention-to-treat analysis showed 18% versus 58% with GALZIN (p=0.023).
-
Faster-Release Reformulation Pushed to 2027
Eton is advancing faster-release formulations and intends to test them in additional study arms in 2027, so a refined ET-700 profile is at least a year away.
Analysis · ETON · Life Sciences
ET-700 is one of six late-stage candidates, and this first human data cuts both ways. Tolerability was clearly better — 1 of 12 ET-700 participants had a treatment-related adverse event versus 8 of 12 on GALZIN — but the efficacy endpoint went the wrong way: hepatic copper uptake fell only 12% on ET-700 versus 46% on GALZIN, and the intention-to-treat analysis showed GALZIN's advantage was statistically significant (p=0.023). Management is pivoting to faster-release formulations with new study arms in 2027, which pushes any meaningful ET-700 readout further out. The commercial franchise (Q2 revenue of $37.6 million, up 99%) is unaffected, so this is a pipeline-timeline story rather than a thesis change.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $47.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.